DrugPatentWatch Database Preview
Drugs in Development Information for INC280
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for INC280?
INC280 is an investigational drug.
There have been 32 clinical trials for INC280.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 31st 2017.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
There are seventeen US patents protecting this investigational drug and two hundred and ninety-one international patents.
Summary for INC280
| US Patents | 17 |
| International Patents | 291 |
| US Patent Applications | 51 |
| WIPO Patent Applications | 37 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2017-05-31) |
| Vendors | 67 |
Recent Clinical Trials for INC280
| Title | Sponsor | Phase |
|---|---|---|
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | Novartis Pharmaceuticals | Phase 2 |
| Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | Novartis Pharmaceuticals | Phase 2 |
| Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for INC280
Top disease conditions for INC280
Top clinical trial sponsors for INC280
US Patents for INC280
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| INC280 | Start Trial | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | Start Trial |
| INC280 | Start Trial | Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide | Novartis AG (Basel, CH) | Start Trial |
| INC280 | Start Trial | Combination therapy | NOVARTIS AG (Basel, CH) | Start Trial |
| INC280 | Start Trial | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,- 4]triazin-2-yl]benzamide and processes related to preparing the same | INCYTE INCORPORATION (Wilmington, DE) INCYTE HOLDINGS CORPORATION (Wilmington, DE) | Start Trial |
| INC280 | Start Trial | Imidazotriazines and imidazopyrimidines as kinase inhibitors | Incyte Corporation (Wilmington, DE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for INC280
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| INC280 | European Patent Office | 3131552 | 2034-04-16 | Start Trial |
| INC280 | Japan | 2017514806 | 2034-04-16 | Start Trial |
| INC280 | Japan | 2019070012 | 2034-04-16 | Start Trial |
| INC280 | New Zealand | 629860 | 2034-04-16 | Start Trial |
| INC280 | World Intellectual Property Organization (WIPO) | 2015160868 | 2034-04-16 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
